| Drug | Class | Adult | Paediatric | Notes |
|---|---|---|---|---|
| Co-amoxiclav (community-acquired, mild)[1] | Aminopenicillin + beta-lactamase inhibitor | 1.2 g IV every 8 h; switch to oral 625 mg TDS once tolerating diet | Per local protocol | First-line for mild community-acquired cholecystitis without severity features; review at 48 h with cultures |
| Piperacillin-tazobactam[1] | Beta-lactam + beta-lactamase inhibitor | 4.5 g IV every 6–8 h | Per local protocol | Moderate-severe or healthcare-associated cholecystitis; broad gram-positive, gram-negative, anaerobic; renal dose adjustment |
| Ceftriaxone + metronidazole[1] | Third-generation cephalosporin + nitroimidazole | Ceftriaxone 1–2 g IV daily + metronidazole 500 mg IV every 8 h | Ceftriaxone 50–80 mg/kg/day; metronidazole 7.5 mg/kg every 8 h | Alternative for mild-moderate community-acquired; oral switch to cefuroxime + metronidazole when improving |
| Meropenem (severe / ESBL risk)[1] | Carbapenem | 1 g IV every 8 h | 20 mg/kg every 8 h | Reserve for severe cholangitis, ESBL coverage, prior multi-resistant organism; renal dose adjustment |
Diagnosis, antibiotic management, and timing of cholecystectomy for acute calculous cholecystitis in adults.